Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.
NPJ Vaccines. 2023 May 10;8(1):67. doi: 10.1038/s41541-023-00662-6.
NPJ Vaccines. 2023.
PMID: 37164959
Free PMC article.
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.
Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, Paz-De la Rosa G, Vigueras-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Domínguez I, Martínez-Guevara JL, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B.
Ponce-de-León S, et al. Among authors: carranza salazar de.
medRxiv [Preprint]. 2022 Feb 9:2022.02.08.22270676. doi: 10.1101/2022.02.08.22270676.
medRxiv. 2022.
PMID: 35169806
Free PMC article.
Preprint.
Item in Clipboard
Cite
Cite